Table 2.
Patients’ clinical data
Patients | Skin lesions | Joint injury | Hematologic abnormalities | Kidney damage | dsDNA | ANA |
---|---|---|---|---|---|---|
1 | P | N | P | N | P | 1:40 |
2 | N | N | N | N | NR | NR |
3 | N | N | N | P | N | 1:20 |
4 | N | N | N | P | N | 1:40 |
5 | P | P | N | P | N | 1:40 |
6 | P | N | N | P | NR | NR |
7 | N | N | N | N | N | 1:80 |
8 | P | N | N | P | P | 1:80 |
9 | N | P | P | P | P | 1:160 |
10 | P | P | P | P | N | 1:40 |
11 | N | N | N | P | N | 1:20 |
12 | N | P | P | P | P | 1:80 |
13 | P | N | N | N | P | 1:80 |
14 | P | N | N | P | N | 1:40 |
15 | N | N | P | N | N | 1:40 |
16 | P | P | N | P | P | 1:40 |
17 | P | N | P | N | N | 1:40 |
18 | P | N | N | N | N | 1:20 |
19 | P | P | P | N | P | 1:160 |
20 | P | N | N | P | N | 1:80 |
21 | P | N | N | P | N | 1:40 |
22 | P | N | N | N | N | 1:320 |
23 | P | P | N | N | N | 1:40 |
24 | N | N | P | P | N | (−) |
25 | P | N | N | P | P | 1:160 |
N negative, P positive, NA not recorded, dsDNA double-stranded DNA, ANA antinuclear antibody